Provided by Tiger Fintech (Singapore) Pte. Ltd.

Senti Biosciences, Inc.

4.43
+0.39009.65%
Post-market: 4.24-0.1900-4.29%18:26 EDT
Volume:24.53K
Turnover:104.20K
Market Cap:115.20M
PE:-0.37
High:4.44
Open:4.01
Low:4.01
Close:4.04
Loading ...

Why Is Senti Biosciences Stock Surging Over 400% On Monday?

Benzinga
·
03 Dec 2024

Senti Bio Shares Catapult After $37.6M Private Placement, Positive Phase 1 Trial

Dow Jones
·
03 Dec 2024

Senti Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
03 Dec 2024

Nasdaq Gains Over 100 Points; Li Auto Delivers 48,740 Vehicles In November

Benzinga
·
02 Dec 2024

Senti Biosciences Shares More Than Triple After Early-Stage Data for Cancer Therapy, Equity Financing; Last up 234.6% at $7.28

THOMSON REUTERS
·
02 Dec 2024

BUZZ-Senti Bio soars after cancer therapy shows promise in early-stage trial

Reuters
·
02 Dec 2024

Senti Biosciences Says 2 Patients Achieve Remission in Phase 1 Blood Cancer Trial

MT Newswires Live
·
02 Dec 2024

Senti Biosciences Shares More Than Double Premarket After Early-Stage Data for Cancer Therapy, Equity Financing ; Last up 156.9% at $5.53

THOMSON REUTERS
·
02 Dec 2024

BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML

Reuters
·
02 Dec 2024

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

THOMSON REUTERS
·
02 Dec 2024

Press Release: Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

Dow Jones
·
02 Dec 2024

Senti Biosciences Inc - Senti-202 Generally Well-Tolerated With Consistent Adverse Event Profile

THOMSON REUTERS
·
02 Dec 2024

Senti Biosciences Inc - Dose Escalation Continuing, Additional Data Expected in 2025

THOMSON REUTERS
·
02 Dec 2024

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of Senti-202, a Logic Gated, Selective Cd33/Flt3-Targeting Car-Nk Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including Aml

THOMSON REUTERS
·
02 Dec 2024

Senti Bio Appoints Fran Schulz to Board of Directors

THOMSON REUTERS
·
02 Dec 2024

Senti Biosciences Q3 EPS $(6.31) Down From $(3.36) YoY; Revenue $0M Down From $0.338M YoY

Benzinga
·
15 Nov 2024

Senti Biosciences Inc: Qtrly Shr Loss $6.31

THOMSON REUTERS
·
15 Nov 2024

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

THOMSON REUTERS
·
15 Nov 2024

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

GlobeNewswire
·
15 Nov 2024

Intel says it lowered stakes in Astera Labs, Joby Aviation, Senti Biosciences

seekingalpha
·
13 Nov 2024